Reduction of Pain Episodes and Prothrombotic Activity in Sickle Cell Disease by Dietary n-3 Fatty Acids

Summary The effects of dietary n-3 fatty acids (n-3FAs) on the frequency of pain episodes and ex vivo blood tests of thrombosis have been evaluated in patients with sickle cell disease (SCD) utilizing a doubleblind, olive oil-controlled clinical trial. Dietary n-3FA therapy (0.1 g/kg/d) was provided...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Thrombosis and haemostasis 2001-06, Vol.85 (6), p.966-974
Hauptverfasser:	Tomer, Aaron, Kasey, Suha, Connor, William E., Clark, Scott, Harker, Laurence A., Eckman, James R.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Anemia, Sickle Cell - blood Anemia, Sickle Cell - complications Anemia, Sickle Cell - drug therapy Anemias. Hemoglobinopathies Biological and medical sciences Biomarkers - blood Blood Cell Count Blood Coagulation Factors - drug effects Case-Control Studies Diseases of red blood cells Double-Blind Method Erythrocyte Membrane - drug effects Erythrocyte Membrane - metabolism Fatty Acids, Omega-3 - administration & dosage Fatty Acids, Omega-3 - pharmacology Fatty Acids, Omega-3 - therapeutic use Female Fibrinolytic Agents - blood Fish Oils - administration & dosage Fish Oils - pharmacology Fish Oils - therapeutic use Hematologic and hematopoietic diseases Humans Male Medical sciences Olive Oil Pain - blood Pain - diet therapy Phospholipids - blood Plant Oils - administration & dosage Plant Oils - pharmacology Plant Oils - therapeutic use Platelet Activation - drug effects Prospective Studies Review Article Thrombophilia - blood Thrombophilia - diet therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Summary The effects of dietary n-3 fatty acids (n-3FAs) on the frequency of pain episodes and ex vivo blood tests of thrombosis have been evaluated in patients with sickle cell disease (SCD) utilizing a doubleblind, olive oil-controlled clinical trial. Dietary n-3FA therapy (0.1 g/kg/d) was provided as menhaden fish oil (0.25 g/kg/d) containing 12% eicosapentaenoic acid (EPA), and 18% docosahexaenoic acid (DHA). Within 1 month dietary n-3FAs exchanged with n-6FAs in plasma and erythrocyte membrane phospholipids (p
ISSN:	0340-6245 2567-689X
DOI:	10.1055/s-0037-1615948